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Introduction. This paper focuses on the application of Magnetic Resonance Spectroscopy (MRS) to the study of Major Depressive
Disorder(MDD)inchildrenandadolescents.Method.AliteraturesearchusingtheNationalInstitutesofHealth’sPubMeddatabase
was conducted to identify indexed peer-reviewed MRS studies in pediatric patients with MDD. Results. The literature search
yielded 18 articles reporting original MRS data in pediatric MDD. Neurochemical alterations in Choline, Glutamate, and N-
Acetyl Aspartate are associated with pediatric MDD, suggesting pathophysiologic continuity with adult MDD. Conclusions.T h e
MRS literature in pediatric MDD is modest but growing. In studies that are methodologically comparable, the results have been
consistent. Because it oﬀers a noninvasive and repeatable measurement of relevant in vivo brain chemistry, MRS has the potential
to provide insights into the pathophysiology of MDD as well as the mediators and moderators of treatment response.
1.Introduction
Led by a major research initiative from the U.S. National
Institute of Mental Health (NIMH), the hunt is on for
biomarkers in psychiatry [1]. A biomarker is a characteristic
that is objectively measured and evaluated as an indicator
of normal biological processes, pathogenic processes, or
pharmacological responses to a therapeutic intervention [2].
The readiness of biological markers to serve as features,
risk factors, or diagnostic criteria is of signiﬁcant concern
in the development of the DSM-V [3], and the research
agenda for DSM-V emphasizes the need to translate research
ﬁndings into a new classiﬁcation for psychiatric disorders
[4, 5]. In psychiatry, biomarkers could be used to detect
and assess or to predict the development of psychiatric
disorders—and more importantly, biomarkers could be used
to inform treatment decisions [6]. It has been argued that
the DSM-V should be structured to permit incorporation
of well-replicated ﬁndings from neuroscience, by creating
mechanisms to ﬂexibly evaluate genetic markers or neu-
roimaging results rather than waiting for publication of the
DSM-VI [7]. A consensus has emerged that advances in the
assessment, treatment, and prevention of brain disorders
are likely to originate from studies based on clinical and
translational neuroscience [8].
In the search for these translational tools, neuroimaging
is a strong candidate to aid psychiatry in its quest to join the
other specialties in medicine in utilizing tests anchored in
biologyfordeliveringcareanddevelopingnewinterventions.
Advances in child psychiatry neuroimaging have begun
to provide a scientiﬁc infrastructure for understanding
numerous psychiatric disorders [9, 10]. Because it can deﬁne
the neural structures and pathways that mediate illness and
its progression, imaging has the potential for use in clinical
decision making and disease monitoring [11]. Owing to the
factthatdepressionisnotassociatedwithgrosstissuepathol-
ogy or with unambiguous animal models for spontaneous
and recurrent episodes, the availability of research tools to2 Depression Research and Treatment
noninvasively assess the brain is critical to elucidating the
neurobiology of mood disorders [12]. In addition to the
scientiﬁc insight they provide, the neuroimaging methods
employed in child and adolescent psychiatry are noninvasive
and have proven to be safe [13].
Child and adolescent psychiatry investigators have
adopted a number of neuroimaging approaches. The pur-
pose of this paper is to review the ﬁndings reported using
Magnetic Resonance Spectroscopy (MRS) in the study of
pediatric Major Depressive Disorder (MDD). As the name
suggests, MRS is a procedure that allows measurement of
relevantneurochemistry.ItsapplicationtothestudyofMDD
is therefore of particular interest, because mood disorders
are illnesses of “state” [14, 15]. If MRS is able to deﬁne
and validate neurochemical biomarkers, then results of MRS
studies may one day be utilized to diagnose mood disorders
and to monitor treatment response.
MDD is a signiﬁcant global health problem, ranking 3rd
on the World Health Organization’s list of the most common
causes of disability worldwide [16]. In the U.S., the National
Comorbidity Survey Replication study found that the peak
age of onset for mental disorders is 14 years, with MDD
most commonly emerging during adolescence [17, 18]. With
an annual incidence of 2% in children and 4% to 8% in
adolescents [19], and a cumulative lifetime prevalence of up
to 20% [20], MDD in children is associated with academic
failure, social impairment, substance abuse, and suicide
attempts [19]. Compared with healthy controls, depressed
adults are more likely to have had a depressive episode in
adolescence [21]. Adding to the morbidity and mortality
experienced by patients and their families, pediatric MDD
imposes a substantial economic burden on society [22].
The personal and ﬁnancial toll is ampliﬁed by the fact
that only 50% of patients with MDD are diagnosed before
reaching adulthood [23]. Therefore, novel diagnostic and
treatment tools for patients in the critical adolescent stage of
development are urgently needed [24–27].
The paper begins with a brief description of how MRS
data is acquired, the information that is obtained, and
how that information diﬀers from the results of other
neuroimaging methods. Following a review of MRS studies
in pediatric MDD, the paper concludes with suggested
directions for further study.
2.Magnetic Resonance Spectroscopy: A Primer
In 1946, Felix Bloch at Stanford University and Purcell at
the Massachusetts Institute of Technology independently
demonstrated the phenomenon of Nuclear Magnetic Reso-
nance (NMR) [28, 29]. It was known that the nuclei of cer-
tain elements, for example, hydrogen (1H) and phosphorus
(31P), have magnetic properties and spin. Bloch and Purcell
showed that nuclei containing an odd number of nucleons
(i.e., protons + neutrons) could absorb energy at a speciﬁc
resonance when placed in a strong magnetic ﬁeld. Based
upon the principles of NMR, magnetic resonance imaging
(MRI) was introduced to clinical medicine in the 1970s [30].
The principles of NMR were used to develop magnetic res-
onance spectroscopy (MRS), which enabled characterization
of living tissues based upon their chemical constituents [31].
Whereas MRI depicts the spatial distribution of protons of
water, which are transformed into a visual representation of
anatomy for interpretation, MRS detects various molecules
present at concentrations on the order of mM (millimolar)
[32]. For a review of the scientiﬁc principles underlying
MRS, the interested reader is referred to the referenced
publications [33–36].
The key distinction between MRI and MRS is the type
of information the magnetic resonance signal is used to
encode. MRI studies create anatomical images whereas MRS
provides quantitative biochemical information about the
tissue under study. Rather than high-resolution images,
MRS data are presented as graphical spectra, with the area
under each peak representing the relative concentration of
nuclei detected for a given atomic species, for example,
hydrogen or phosphorus. The x-axis of graphed MRS data
denotes the frequency shift localizing the metabolite in parts
per million. MRS spectra peaks correspond with speciﬁc
chemical compounds of interest. Thus, MRS non-invasively
provides a repeatable measure of chemical concentration
data in living tissues, including the human brain. For the
patient, the procedure is identical to a clinical study except
for the amount of time spent in the scanner; the duration
ranges from less than 10 minutes for acquisition of proton
spectra to approximately 30 minutes for a phosphorus scan.
MRS scans use no radiation, which allows for repeated
measurement at diﬀerent times in the course of a patient’s
illness, for example, prior to the start of treatment and at the
point that remission is achieved. Figure 1 shows an example
of 1H-MRS spectrum obtained from the anterior cingulate
cortex of a patient with MDD.
The chemicals quantiﬁable with 1H-MRS include the
following: N-Acetyl-Aspartate (NAA), creatine (Cr), choline
(Cho), myoinositol (mI), and lactate (Lac). The term “GLX”
(Glx) is used to designate the single peak containing the
amino acid neurotransmitters Glutamate (Glu), Gamma-
Aminobutyric Acid (GABA), and Glutamine (Gln) [37],
because 1H-MRS signals from Glu and Gln are complicated
by the interaction of neighboring protons and the pH
dependenceofchemicalshift[38].Gluisthemajorexcitatory
neurotransmitter in the human brain and was ﬁrst measured
in 1992 [39]. Brain in vivo concentrations of Glu are
approximately 8–13 times that of GABA, and the ratio
of Glu/Gln ranges from 2.4–3.8; therefore, alterations in
Glx are typically attributed to altered Glu concentrations
[40]. GABA, the major inhibitory neurotransmitter in the
brain, has an 1H-MRS peak that can be separated from Glx
at magnetic ﬁeld strengths ≥2Tesla using spectral editing
technique or 2-D J-resolved spectra [41].
NAA is the most prominent 1H-MRS peak and is found
only in the nervous system [42]. It is a marker of neuronal
density or function, osmoregulation, and energy homeosta-
sis; there is a direct relationship between NAA synthesis,
oxygen consumption, and ATP production in the central
nervous system [43] .N A Am a ya l s op l a yac r i t i c a lr o l ei n
myelin production within oligodendrocytes [44]. Reduction
i nN A Al e v e l sm e a s u r e db y1H-MRS is a recognized marker
of neuronal loss or dysfunction in several psychiatric andDepression Research and Treatment 3
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Figure1:Representativeproton(1H)magneticresonancespectrum
of the anterior cingulate cortex at 3Tesla (TR = 2000ms, TE = 135).
Cho = Choline; Cr = Creatine; Glx = Glutamine + Glutamate; NAA
= N-Acetyl Aspartate; ppm = parts per million.
neurological disorders including drug abuse, schizophrenia,
traumatic brain injury, stroke, epilepsy, multiple sclerosis,
neoplasm, HIV encephalopathy, and Alzheimer’s disease
[43].
The Cr peak reﬂects the sum of the Cr and Phos-
phocreatine (PCr) peaks, an important limitation that will
be discussed below. The equilibrium maintained between
Cr and PCr is determined by the cellular demand for
the high-energy phosphate stored as creatine phosphate
[45]. As its level is considered to be constant, Cr is often
used as an internal standard for comparison [46]. The
Cho peak contains four membrane- and myelin-related
chemicals [36]: phosphorylethanolamine (PE), phosphoryl-
choline (PC), glycerophosphorylethanolamine (GPE), and
glycerophosphorylcholine (GPC). Cho is a metabolic marker
ofmembranedensityandintegrity,thatis,phospholipidsyn-
thesis and degradation [30]. Neuropathology characterized
by cell membrane breakdown liberates Cho and increases the
freeChopool,contributingtoanincreasedresonanceinneu-
rodegenerativedisorders[45].Intraumaticbraininjury,Cho
levels increase in relation to the severity of neuronal injury
resulting from the breakdown of membranes and myelin
[47]. Finally, an elevation in the Cho resonance within brain
lesions has been accepted as a sign of malignancy [48, 49].
Myoinositol (mI) is a sugar involved in the regulation of
neuronal osmolarity, the metabolism of membrane bound
phospholipids, and in the phosphoinositide (PI) secondary
messengerpathway[46].Myo-inositolisconsideredamarker
of glial proliferation, and an increase in mI resonance may
be a proxy for increased inﬂammation in the brain [50].
Under normal circumstances, lactate (Lac) is present in the
brain at concentrations too small to be detected using 1H-
MRS. However, if the aerobic oxidation mechanism fails and
anaerobic glycolysis is triggered—such as brain ischemia,
hypoxia,seizureactivity,andmetabolicdisorders—Laclevels
risesigniﬁcantly[30].Typically,theLacpeakcanbeobserved
as an inverted doublet at an echo time of 135ms at 1.3ppm.
It has been shown that lactate becomes elevated if large
numbers of inﬂammatory cells are activated [51]. In the past
two decades, 1H-MRS has progressed from the laboratory
into routine use in the treatment of cancers of the brain
and prostate [33]. Mood disorders may join the list of
disease states in which clinicians can make use of 1H-MRS,
if the current pace of neuroimaging research in psychiatry is
maintained.
31P-MRS is a related neuroimaging method that acquires
the resonance spectra of phosphorus rather than hydrogen.
Although MRS can be performed on a variety of nuclei such
as carbon, nitrogen, ﬂuorine, and sodium, only the nuclei
of phosphorus (31P) and hydrogen (1H) exist in vivo in
suﬃcient concentrations for routine clinical evaluation [52].
Studies employing 31P-MRS have indicated possible abnor-
malities in membrane high-energy phosphate metabolism,
phospholipid metabolism, and intracellular pH in mood
disorders [32].
In 31P-MRS spectra of the brain, seven chemical peaks
are resolved; these are phosphomonoester (PME), inorganic
phosphate (Pi), phosphodiester (PDE), phosphocreatine
(PCr), and alpha-(α), beta-(β), and gamma-(γ) nucleoside
triphosphate (NTP) [32, 53, 54]. Figure 2 displays an exam-
ple of the spectra that is acquired.
The β-NTP peak is measured as a proxy for ATP, the
principal energy source in brain. The phosphomonoester
(PME)peakcontainsthesignalsfromnumerousmetabolites,
including those related to membrane phospholipid synthesis
such as phosphocholine (PC) or phosphoethanolamine (PE)
[55] and sugar phosphates such as glycerophosphate or
inositol phosphates [56]. In the PME region, PE is the most
abundant and PC is the second most abundant metabolite
[57]. The membrane breakdown products glycerophospho-
choline and glycerophosphoethanolamine contribute to the
PDE peak [58], but most of the signal in the in vivo PDE
peak arises from membrane phospholipid itself [59, 60],
marking PDE as a marker of neuronal integrity. The Pi peak
appears between the PME and PDE peaks. Pi appears in
many metabolic pathways. Although the Pi peak contains
both PO4
−1 and PO4
−2, they register as one peak due to the
rapid exchange between these two molecules. The position
of this peak reﬂects the equilibrium between PO4
−1 and
PO4
−2, a fact that allows investigators to calculate brain
pH from the chemical shift of the Pi peak [61]. Because
the phosphate ions exist in the intracellular space, this
calculated pH reﬂects intracellular pH (pHi). The PCr peak
is the most prominent peak in the 31P-MRS spectra in the
brain [32]. PCr conveys high-energy phosphates from the
mitochondria to the cytosol. When an ATP molecule is
consumed, PCr transfers its high-energy phosphate group
to ADP (adenosine diphosphate), thus replenishing ATP via
the creatine kinase reaction. In this regard, PCr behaves4 Depression Research and Treatment
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Figure 2: Phosphorus (31P) magnetic resonance spectrum of the
whole brain at 3Tesla (TR = 3000ms, TE = 2.3ms). PME = phos-
phomonoester; Pi = inorganic phosphate; PDE = phosphodiester;
PCr = phosphocreatine; NTP = Nucleoside Triphosphate; ppm =
parts per million.
as a buﬀer of ATP [62]. PCr is abundant in tissues with
rapidly variable energy demands, that is, brain and muscle
tissue. This ATP buﬀer is absent in tissues where energy
demands are constant, such as liver tissue. NTP forms
three distinct peaks—alpha-(α), beta-(β), and gamma-(γ)
nucleoside triphosphate—of which the doublet of the γ-
ATP peak is resolved in 31P-MR spectra [32]. ATP is the
bioenergetic substrate for many biochemical processes in the
brain and is present at a much higher concentration—on the
order of 1.8mM—than any other NTP [63].
For a number of practical reasons, proton spectroscopy
is the most widely employed MRS method in psychiatric
research. Protons are abundant in organic structures, and
their nuclei have high magnetic sensitivity. In 1995, 1H-
MRS became widely available when the U.S. Food and
Drug Administration (FDA) approved the software for an
automated and inexpensive MRS sequence protocol, the
PROton Brain Examination (PROBE) [31, 64], which can
be run without dedicated research personnel on a standard
MRI scanner [31]. The majority of 1H-MRS studies have
been conducted using MRI scanners operating at magnetic
ﬁeld strengths of 1.5Tesla or less, which is less than optimal
for 31P-MRS. However, 3Tesla MRI was approved by the
FDA in 2000 [65] and is becoming widely accessible to
major medical centers. The increased availability of scanners
with 3 or 4Tesla magnetic ﬁelds will improve the sensitivity
of MRS studies [66]. At present, to conduct MRS brain
scans that target other nuclei of interest to psychiatrists—
such as phosphorus or lithium—requires specialized equip-
ment (though not a separate MRI machine!) and research
expertise. These obstacles will not be insurmountable, if
31P-MRS, in particular, proves to be a valid and reliable
measure of one or more translational biomarkers in the
aﬀective disorders. To date, unlike physicians in other ﬁelds
of medicine, psychiatrists do not beneﬁt from working with
objective measures of illness and recovery, such as blood
pressure or hemoglobin A1c. In the competition to deﬁne
the ﬁrst validated biomarker for use in clinical psychiatry,
MRS investigators have joined the pursuit along with their
colleagues in genetics, neuroscience, and other branches of
neuroimaging.
In recent years, multiple studies have reported regional
and global hypometabolism in subjects experiencing a major
depressiveepisode,whichcouldberelatedtothepathophysi-
ologyofmooddisorders[67].Theliteraturedescribessev eral
abnormalities of bioenergetic metabolism in adults, primar-
ilydecreasedbaselinelevelsofβ-nucleosidetriphosphateand
total NTP, in the basal ganglia and the frontal lobes of MDD
subjects compared with healthy control subjects [63, 68, 69].
Our group recently reported baseline PCr levels could be
a predictor of depression treatment outcomes [67]. Thus,
31P-MRS provides investigators with a robust methodology
[70], with which it is now possible to test speciﬁc hypotheses
regarding the neurobiology of mood disorders in adults.
MDD is a common and disabling illness that often begin in
adolescence [23, 71–73]. Given the well-established safety of
MRI, further study of pediatric mood disorders utilizing 31P-
MRS represents a rational endeavor in an attempt to expand
the evidence base in medicine.
3.MaterialsandMethods
3.1. Search Strategy. A literature search using the U.S.
National Library of Medicine’s PubMed database was
conducted to identify peer-reviewed neuroimaging MRS
research studies of children and adolescents with MDD
that were published between January 1966 to March 2010.
The following terms were included in the search: “mag-
netic resonance spectroscopy,” “depressive disorder,” “mood
disorder or aﬀective disorder,” and “child or adolescent or
pediatric or early-onset.” We performed a backward search
of bibliographic references from the identiﬁed articles to
ensure the inclusion of relevant articles. A forward citation
search for identiﬁed studies was also performed. Studies that
recruited a mixture of adults and children were not included.
All relevant articles published in English were included,
and due to the small number of studies no methodological
exclusion criteria were applied.
4. Results and Discussion
The literature search yielded 18 articles reporting original
MRS data in pediatric MDD: 13 studies in MDD and
5 in children and adolescents with mood disorders not
meeting full diagnostic criteria for MDD. Table 1 presents
the published MRS studies in pediatric MDD, all of which
employed 1H-MRS.Depression Research and Treatment 5
Table 1: Magnetic resonance spectroscopy studies of pediatric major depressive disorder.
Study Sample Field
strength Voxel size & location Findings
Caetano,
et al. 2005
[83]
-14 MDD (mean age
13.6)-22 Healthy
Controls (mean age
13.3)
1.5 Tesla 8cc in the Left Dorsolateral
Prefrontal Cortex
⇓ glycerophosphocholine +
phosphocholine (GPC + PC; or
choline-containing compounds) in
MDD patients. ⇑ Inositol and
myo-Inositol levels in MDD patientsIn
MDD patients Glutamate level is
inversely correlated with Duration of
I l l n e s sa sw e l la sN u m b e ro fE p i s o d e s
Farchione
et al. 2002
[76]
-11 treatment-naive
MDD patients (mean
age 14.3)-11 healthy
controls (mean age
14.3)
1.5 Tesla
0.8 cc in the Left and Right
Dorsolateral Prefrontal
Cortex
⇑ Cho was observed in left (but not
right) DLPFC in MDD patients versus
healthy controls (32.5% higher)No
diﬀerence in NAA or Cr were observed
between case-control pairs
Gabbay
et al. 2009
[89]
-7 MDD patients
(mean age 16.2) with
Melancholic
Features-7 patients
(mean age 16.9) with
non-melancholic,
reactive MDD-6
healthy comparison
patients (mean age
16.2)
3T e s l a
10 cm anterior–posterior
(AP) × 7 cm left–right (LR)
× 6 cm inferior–superior
(IS) = 420 cm3 in the Left
Putamen and Right
Caudate
No signiﬁcant correlations were found
in the healthy control group or in the
MDD group as a wholeIn Melancholic
patients, plasma Kynurenine
concentrations were positively
correlated with Right Caudate total
CholineIn Melancholic patients, plasma
3-hydroxyanthranilic acid (3-HAA), a
neurotoxic intermediate of the
Kynurenine Pathway) was positively
correlated with Left Putamen total
Choline
Gabbay
et al. 2007
[86]
-14 adolescents(mean
age 16.2 years) who
had symptoms of
M D Df o r8w e e k sa n d
as c o r e≥40
(mean=63.6) on the
Children’s Depression
Rating
Scale—Revised-10
healthy comparison
patients
3T e s l a
16 (anterior-posterior) ×
16 (left-right) voxels, each
anominal 0.75 cm3in the
left and right caudate,
putamen and thalamus
Adolescents with MDD had signiﬁcantly
⇑ concentrations of choline (2.11mM
versus 1.56mM) and creatine (6.65mM
versus 5.26mM) in the left caudate.No
other neurochemical diﬀerences were
observed between groups
Kusumakar,
et al. 2001
[75]
-11 MDD (mean age
16.7)-11 Healthy
Controls (mean age
16.6)
1.5 Tesla
Multivoxel: 6x6 placed in
anterior medial temporal
region (amygdala)
⇓ Left amygdala Cho-Cr ratios in MDD
patients compared with controlsLeft
amygdala NAA-Cr and right amygdala
Cho-Cr and NAA-Cr did not diﬀer
signiﬁcantly between patients with
depression and control patients
MacMaster
et al. 2008
[87]
11 MDD, 11 Healthy
Controls 1.5Tesla
0.8 mL voxel in the left and
right Medial Temporal
Cortex
⇓ N-acetyl-aspartate in theleft medial
temporal cortex (27%) in MDD
patients versus healthy controls
MacMaster
and
Kusumakar,
2006 [84]
-12 MDD-11 Healthy
Controls (10-18 y/o; 7
females and 5 males
per group)
1.5 Tesla 4cc in the right prefrontal
cortex
⇑Right prefrontal cortex
Choline/Creatine ratio in MDD
compared with healthy controls
(p = .007)
Mirza et al.
2004 [80]
-13
psychotropic-na¨ ıve
with MDD (mean age
15.5)-13 healthy
controls (mean age
15.4)
1.5 Tesla
2 × 1.5 × 1c m= 3c c
volume centered on the
anterior cingulate cortex
Anterior cingulate glutamatergic (Glx)
concentrations were signiﬁcantly ⇓
(19% decrease) in MDD patients versus
controls (9.27 +/- 0.43 versus 11.47 +/-
0.26, respectively, p = .000)6 Depression Research and Treatment
Table 1: Continued.
Study Sample Field
strength Voxel size & location Findings
Mirza et al.
2006 [85]
18 pediatricpatients
with major depressive
disorder 9 to 17 years
of age, 18
case-matched healthy
controls, and 27
patients
withobsessive-
compulsive disorder 7
to 16 years old
1.5 Tesla 0.8 mL voxel in the medial
thalamus
⇑ left and right medial
thalamiccreatine-phosphocreatine
concentrations in patients with OCD
compared with both healthy controls
and patients with
MDDCreatine-phosphocreatine
concentrations did not diﬀer
signiﬁcantly betweenpatients with
MDD and healthy controls
Rosenberg
et al. 2005
[82]
14 MDD patients
(man age 15.6)14
healthy controls
(mean age 15.5)
1.5 Tesla
2 × 1.5 × 1c m= 3cc
centered on the Anterior
Cingulate Cortex
⇓ anterior cingulate glutamate in MDD
patients compared with controls
(p = .0002; 23% decrease) No diﬀerence
in anterior cingulate glutamine
Rosenberg,
et al. 2004
[81]
-14
psychotropic-na¨ ıve
patients with
MDDwithout OCD
(mean age 15.6)-20
non-depressed,
patients with OCD
(mean age 11.4)-14
healthy controls
(mean age 15.5)
1.5 Tesla
2 × 1.5 × 1c m= 3mL in
the Anterior Cingulate
Cortex
⇓Anterior cingulate glutamatergic
(Glx) concentrations were signiﬁcantly
in OCD patients (15.1% decrease) and
MDD patients (18.7% decrease)
compared with controls (p = .002)
Smithetal.
2003 [77]
- 1 8d r u gn a i v e
outpatients with
MDD without OCD
(mean age 14.4)-27
drug-naive patients
with OCD (mean age
10.3)-18 healthy
controls (mean age
14.4)
1.5 Tesla
0.8 mL voxel in the left and
right medial and lateral
thalamus
⇑ left and right medial thalamic
Choline concentrations in OCD
patients compared with both healthy
controls and patients with MDD
Steingard,
et al. 2000
[74]
-17 MDD patients
(mean age 15.8)-28
healthy controls
(mean age 14.5)
1.5 Tesla
15 mm x 15 mm x 15 mm
(3.38cm3) voxel in the Left
Orbitofrontal Cortex
⇑ Choline/Creatine ratio in MDD
compared with controls⇑ Choline/NAA
ratio in MDD compared with controls
Following up on their report of structural abnormali-
ties in the brains of children hospitalized for depression,
Steingard and colleagues reported in 2000 ﬁnding increased
choline/creatine ratios and increased choline/NAA ratios in
the left orbitofrontal cortex of adolescents with MDD com-
pared with controls [74]. This suggested that brain cytosolic
choline may be increased in depressed adolescents, indepen-
dent of corresponding structural changes, results that were
consistent with studies in adults with MDD. This report
was followed in 2001 by Kusumaker’s ﬁnding of decreased
choline/creatine ratios in the left amygdala [75], which again
implicatedcholineinthepathophysiologyofpediatricMDD.
In 2002, Farchione et al. studied the left and right dorsolat-
eral prefrontal cortex in medication-na¨ ıve adolescents with
MDD and healthy controls. A signiﬁcant increase in choline
was observed in left—but not right—dorsolateral prefrontal
cortex in MDD patients versus controls (32.5% higher) [76].
In a three-armed 1H-MRS study, Smith et al. compared
medication-na¨ ıveMDDpatientswithObsessive-Compulsive
Disorder (OCD) patients and healthy controls. Following
up on a prior ﬁnding of choline alterations in OCD, the
investigators studied the thalamus and found increased
choline concentrations bilaterally in the medial thalamus in
pediatric OCD patients compared with both MDD patients
and controls; they found no diﬀerence in medial thalamic
choline between MDD patients and control subjects [77].
The potential of MRS in pediatric mood disorders was
conﬁrmed by these initial studies in pediatric MDD, which
joined studies in adult MDD and preclinical animal research
in implicating choline alterations in the disorder [78, 79].
Two pediatric MDD 1H-MRS studies were published
in 2004. Mirza et al. compared medication-na¨ ıve patients
with healthy controls and found a 19% decrease in glu-
tamatergic (Glx) concentrations in the anterior cingulateDepression Research and Treatment 7
cortex in the MDD patients [80]. A second study of the
anterior cingulate cortex found lower Glx concentrations
in both MDD patients (18.7% decrease) and OCD patients
(15.1% decrease) compared with healthy controls [81]. In
the following year, two additional studies were published.
Rosenberg et al. separated the Glutamate and Glutamine
peaks and found 23% lower Glutamate concentrations in the
anterior cingulate cortex of MDD patients compared with
controls(P = .0002)[82].Caetanoandcolleaguesconducted
a case-control study of the left dorsolateral prefrontal cortex
and reported decreased choline-containing compounds and
increased myoinositol concentrations in patients with MDD
[83].MacMasterandKusumakarreportedresultsoftheir 1H-
MRS study of the right prefrontal cortex in 2006, ﬁnding
that choline/creatine ratio was elevated in MDD patients
compared with healthy controls [84]. That same year, Mirza
et al. published a study comparing patients with OCD with
MDD and control subjects. The OCD patients demonstrated
increased choline/Phosphocreatine concentrations in the left
and right medial thalamus [85].
In recent years, investigators have expanded the range
of structures and metabolites under study. Gabbay et al.
reported in 2007 that adolescents with MDD had increased
concentrations of both choline and creatine in the left (but
not the right) caudate nucleus [86]. In 2008, MacMaster et
al. were the ﬁrst to report alterations in NAA in pediatric
MDD, ﬁnding a 27% decrease in NAA in the left medial
temporal cortex in aﬀe c t e ds u b j e c t sv e r s u sh e a l t h yc o n t r o l s
[87]. Finally, Gabbay and colleagues obtained proton spectra
with a 3Tesla scanner and produced ﬁndings that begin to
parse the subtypes of pediatric mood disorders on a neuro-
biological level by focusing on immune system dysregulation
in pediatric MDD [88]. The investigators reported that in
patients with melancholic features, plasma Kynurenine levels
were positively correlated with choline concentrations in the
right caudate nucleus and plasma 3-hydroxyanthranilic acid,
a neurotoxic intermediate of the Kynurenine Pathway, was
positively correlated with left putamen total choline [89].
Taken together, the consistency of ﬁndings in pediatric
MDD validates the utility of MRS as a translational tool for
studying pediatric MDD and adds to the converging lines of
evidence suggesting that pediatric MDD is continuous with
adult MDD [90].
5. Conclusions
A decade ago, Hendren et al. reviewed the neuroimaging
literature in child and adolescent psychiatry and called for
researchers to “identify clear structure/function hypotheses
when studying childhood mental disorders that use but go
beyond DSM diagnoses [91].” Echoing this sentiment, the
research agenda for DSM-V emphasizes the need to translate
ﬁndings from clinical neuroscience research into a new clas-
siﬁcationsystembaseduponpathophysiologyandetiological
processes [92, 93]. As it continues to mature as a method,
MRSispositionedtomakeacontributiontothisevolutionin
psychiatry.In vivo MRSistheonlynoninvasiveimagingtech-
nique capable of directly assessing the living biochemistry in
localized brain regions [94]. Studies of depressed children
and adolescents have a number of advantages compared
with studies of adults: the eﬀects of statistical covariates
such as repeated episodes, duration of illness, multiple
medications, and normal aging are avoided. Thus, MRS may
be a translational research tool capable of partially obviating
thedevelopmentalandenvironmentalconfoundersthathave
made research in child psychiatry a diﬃcult challenge.
Researchers working with pediatric MDD populations
have reported MRS ﬁndings that implicate Glx, NAA, and
choline (including its correlation with immune system
metabolites) in the neurobiology of MDD. Altered levels of
choline would be consistent with altered neural plasticity
as well as animal models of depression and antidepressant
response [95]. No study identiﬁed in our literature search
used repeated measures MRS scans to ascertain if there are
changes in neurometabolite concentrations when a child
with MDD responds to treatment, that is, whether the
baseline diﬀerences in Glx, NAA, and choline are diﬀerences
of “state” or “trait”. Pavuluri and Sweeney have argued
for the importance of obtaining functional neuroimaging
measures before and after pharmacologic intervention [9],
andthe feasibility of this approachis demonstrated in several
published studies of depressed adults [67, 96, 97]. Results
from such studies will shed light on the mechanisms by
which antidepressants work and may provide new treatment
targets for drug development [13, 98]. In addition to
pointing toward the mechanisms of illness recovery (i.e., the
“mediators” [99]), Pavuluri also emphasizes the potential
for neuroimaging studies to identify predictors of treatment
outcome [9] (i.e., the “moderators” [99]). Identiﬁcation of
the mediators and moderators of pediatric MDD treatment
would serve the NIMH’s stated goal of moving toward
personalized care.
Research in mood-disordered adults [67, 68, 100–103],
combined with preclinical animal studies of depression
[104–107], has given rise to the bioenergetic hypothesis,
whichproposesthatalteredenergymetabolismisareversible
correlate of pathogenesis of mood disorders [108–110].
Converging lines of evidence from electron microscopy, gene
expression, genotyping, and sequencing studies implicate
mitochondrial dysfunction in MDD [111]. Neuroimaging
studies using MRS have convincingly demonstrated that
MDD is associated with mitochondrial dysfunction [73, 77–
79, 112]. More speciﬁcally, a growing body of research
shows that MDD subjects have decreased beta nucleoside
triphosphate (b-NTP) and increased levels of phosphocrea-
tine (PCr) compared with healthy controls [73, 78, 79]. Fur-
thermore,successfultreatmentofMDDwithantidepressants
is associated with normalization in both NTP and PCr levels
[79, 112].
Contemporary understanding of the neurobiology of
depression is focused on imbalances in neural circuits [12],
cellular plasticity and resilience [113, 114], and impaired
neurotrophic signaling cascades [115]( f o ra ne x c e l l e n t
review, see Carlson et al. [116]; for the conceptual frame-
work, see and Manji et al. [117] and Duman et al. [118]). As
aresearchtool,MRSisuniqueinitsabilitytoperforminvivo
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integrity, mitochondrial functioning, cellular membrane
turnover, and signaling cascades [66]. Finally, MRS is the
only known method for in vivo measurement of gamma-
aminobutyric acid (GABA) concentration [41, 119], which
plays an increasingly central role in our conceptualization of
mood disorders [120–123]. As the ﬁeld matures, it has the
potential to play a major role in delineating the neurobiology
of MDD.
5.1. What Are the Limitations of MRS? While MRS studies
have the potential to provide unique insights into the
neurobiology of pediatric MDD, technical limitations must
be acknowledged. As with all neuroimaging modalities,
the number of patients enrolled in a given study tends
to be small. Comparison between studies (and therefore
replication of key ﬁndings) is diﬃcult, due to diﬀerences in
spectra acquisition protocols and the fact that calculation of
the area under a given spectral peak is open to considerable
interpretation [36]; the optimal method for quantiﬁcation
of neurochemicals has yet to be determined. In addition,
the generalizability of MRS studies is limited by potential
confounds such as medication eﬀects, duration of illness,
comorbidity, and gender [124]. At present, MRS has less
temporal and spatial resolution compared with MRI and
functional MRI (fMRI) [125]. The volume of the brain—
called the “voxel”—that is sampled in a typical 1H-MRS
study is ≤8mL (larger for 31P-MRS scans). This is problem-
atic in the light of current models of depressive disorders,
which suggest the presence of altered interactions between
hierarchically distributed neural networks which are widely
distributed throughout the brain [126]. Another issue is the
relatively small number of metabolites that can be assayed
using MRS. “Key players” such as dopamine, serotonin, and
norepinephrine are not visible to an MRS scanner [38].
Finally, scanning times are relatively long (up to 90 minutes),
which increases the burden on research participants and
limits patient acceptance.
5.2. What Would a Child Psychiatrist Want to Know about
MRS? With the current emphasis on translational research
in medicine, the question of science’s relevance to practicing
clinicians is ever-present. Busy child and adolescent psychi-
atrists are faced on a daily basis with questions that further
study utilizing MRS has the potential to answer.
(i) How can we distinguish bipolar disorder (BD) from
MDD? Chang et al. posed the question of whether
neuroimaging will be used to diagnose BD in a 2006
publication, concluding that use of MRS variables
such as mI or NAA for diagnosis is problematic at
present, due to the variable of mood state and the
lack of standardized methods for performing and
interpreting the scans [112]. If children with both BD
and MDD were followed and scanned longitudinally,
MRS would be able to test the hypothesis that
the major depressive episodes experienced by both
groups of patients have the same neurochemical
basis.
(ii) What is a problem of state versus a problem of
trait? The ability of MRS to measure neurochemical
changes that parallel changes in patients’ clinical
presentation is now well established in children and
adults. In addition, further study of children and
adolescents would help determine whether diﬀer-
ences in depressed patients are the result of altered
development across the life span, or if they can
be documented early in development, serving as a
risk factor for which prevention strategies might be
employed [74].
(iii) Can MRS help clinicians assess the eﬀects of med-
ication? Our literature search did not ﬁnd any
publications utilizing MRS to measure changes in the
brain in pediatric MDD treatment studies.
(iv) What is the speciﬁcity of MRS in mood disorders?
The results thus far suggest that MRS can ﬁnd
neurochemical diﬀerences between mood disorders
and OCD [77], Intermittent Explosive Disorder
[127], and Attention-deﬁcit Hyperactivity Disorder
(ADHD) [128].
An illustrative example of the potential for speciﬁcity
oﬀered by MRS is the case of Glx and ADHD. Investigators
have found elevated Glx in brain regions of interest in
ADHD patients compared to healthy controls.Duman et al.
[118] found increased Glx in the right prefrontal cortex and
striatum of ADHD subjects, Courvoisie [119]d o c u m e n t e d
increasedGlxintheleftandrightfrontallobes,andKlempan
etal.[120]foundelevatedGlxconcentrationsinthestriatum
treatment-na¨ ıve ADHD patients. In addition, Carey et al.
have shown that changes in glutaminergic tone occur with
ADHD treatment [129, 130]. In contrast to the ﬁndings in
ADHD, Rosenberg [81]a n dM i r z a[ 80] have shown that
Glx is reduced in MDD, and Moore et al. [128]f o u n d
that pediatric Bipolar Disorder with and without ADHD is
diﬀerentiated by Glx concentrations in the anterior cingulate
cortex.
5.3. What Should Future MRS Studies in Pediatric Mood
Disorders Look Like? Some twenty years ago, Bottomley
enumerated the “trouble with spectroscopy papers” [131],
lamenting the fact that a research tool with such precision
had given rise to a medical literature whose ﬁndings are
not easily reconciled. Noting the lack of standards for the
conduct and reporting of clinical MRS research, Bottomley
recommended that authors provide objective, rigorously
quantiﬁed results and that spectra acquisition protocols
be described in suﬃcient details that experiments could
be reproduced [131]. More recently,Kreis [132]a n dT a y l o r
[133] have argued cogently for the ﬁeld of clinical MR
spectroscopy to establish a set of scientiﬁc and quality
assuranceguidelines.Thisprocessisunderwayinoncological
neuroradiology [134–136], but widely accepted standards
have yet to be established in psychiatry. As shown in Table
1, the MRS literature in pediatric MDD presents the reader
with a diversity of techniques, anatomical reference points,
and neurochemical ﬁndings. Future studies would beneﬁtDepression Research and Treatment 9
from standardized protocol design and data reporting:
as Leibenluft [13] has observed, psychiatric neuroimaging
articles can be “confusing, tedious to read and...boring”—
even for researchers in the ﬁeld. For MRS studies of mood
disorders to become a truly translational body of research,
investigators will need to communicate their ﬁndings to the
widerpsychiatriccommunityinaclearandintuitivemanner;
establishmentofanexpertconsensusregardingbestpractices
in MRS research and reporting would be a signiﬁcant early
step toward that goal.
Two important gaps in the medical literature were
identiﬁedbythePubMedsearchonwhichthispaperisbased.
The ﬁrst is that there were no peer-reviewed publications
reporting 31P-MRS data in pediatric MDD. 31P-MRS has
the unique ability to measure high-energy phosphorus
metabolites in vivo [63, 68, 69, 137], which is important
because dysfunction in neuronal energy metabolism may be
one mechanism of depression [109]. Second, no pediatric
MDD clinical trials were identiﬁed in which MRS brain
scans were used as a repeated measure, that is, performed
pre- and posttreatment in order to learn which, if any, MRS
metabolites werealteredbythe study treatmentintervention.
In contrast to their absence in the pediatric MDD literature,
repeated measures MRS scans have often been incorporated
into treatment studies of pediatric Bipolar Disorder [138–
141] and related conditions [142, 143]. Incorporating 31P-
MRS methodology and repeated measures study design into
pediatric MDD clinical trials could provide fundamental
insights into the neurobiology of MDD.
In conclusion, MRS is an emerging translational research
tool for the study of pediatric MDD. The bulk of published
MRSdepressionstudieshavebeendoneinadultpopulations,
but mood disorders often begin in adolescence and there
is much to be learned by studying young people who are
early in the course of the disorder. The non-invasive nature
and relative safety of MRS make this possible. Well-designed
future MRS studies in pediatric MDD will shed light on the
neurobiology of depression, help to deﬁne the physiologic
mechanisms illness and recovery, and identify treatment
targets for the development of new interventions.
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